Meibography visualizes meibomian gland structure and can help document gland loss or change over time. It is usually interpreted alongside symptoms and other ocular surface tests rather than used alone.
Dry Eye in Optometry: When Is Follow-Up Really Needed?
A peer-level look at how optometrists are moving chronic dry eye care from symptom relief toward mechanism-driven diagnosis, procedures, and longer-term patient commitment.
Total responses: 35
Complete responses: 22
Countries: 4
Survey ID: 8884321
Quick Read — Key Findings
👁️
47.8%
🔍
86.4%
📋
40.9%
🕒
31.8%
💧
63.6%
💼
77.3%
Read the full MDForLives insight report
Explore the full story, exact response patterns, clinical or operational implications, and peer voice themes.
Dry eye has outgrown the drop bottle, but the care pathway remains uneven
Dry eye is no longer understood as a single symptom treated with a universal lubricant. TFOS DEWS II describes it as a multifactorial ocular surface disease involving tear-film instability, inflammation, tissue damage, and neurosensory factors. That broader view has created new diagnostic and treatment choices, but it has also made practice design more demanding.
We asked practicing optometrists across the United States, Canada, Italy, and France how they are managing this shift. The results reveal a field in transition: advanced therapeutics are common, procedural care is growing, Demodex screening is changing examination behavior, and patient acceptance often stalls at cost rather than clinical interest.
81.9%
Most practices are beyond basic care, but only a minority identify as procedural centers
The field is not divided neatly between modern and traditional care. Most practices sit in the middle, with stronger therapeutics but limited procedural infrastructure.
What the pattern means: Nearly three-quarters describe either advanced procedural or prescription-led care, confirming that dry eye is being medicalized across optometry. Yet only 26.1% identify as advanced procedural centers, so clinical capability is moving faster than protected schedules, equipment plans, and technician support.
Practice insight: Adding a procedure is not the same as building a procedural pathway. Practices need clear diagnostic entry criteria, dedicated appointment types, staff roles, and follow-up ownership before advanced care can become routine.
For most optometrists, procedures begin after the first pathway has already failed
Most optometrists position in-office treatment as the next step after drops, masks, or prescriptions fail rather than as an early mechanism-based intervention.
What the pattern means: With 52.2% using procedures as step-two therapy and only 17.4% presenting them immediately, advanced care often begins after adherence or symptom control has already weakened. The pathway is therefore reactive even when the diagnosis is mechanism driven.
Practice insight: Objective transition points, such as persistent symptoms, visible gland dysfunction, or inadequate response after a defined interval, can make escalation more consistent and reduce prolonged cycling through low-yield home care.
Demodex attention has risen because the finding now leads somewhere
A diagnosis changes routine behavior most quickly when clinicians have a specific action to take after recognizing it.
What the pattern means: Screening behavior has changed for 86.4%, but only 40.9% report a universal protocol. Symptom-triggered inspection remains slightly more common, which leaves detection dependent on whether patients recognize or report itching and redness.
Practice insight: A brief, standardized lid-margin check can make detection less dependent on symptom language and better connect the examination to targeted treatment decisions.
Imaging helps explain the disease, but cost still decides whether treatment moves forward
Clinical explanation helps patients understand disease, but the largest barrier appears when the treatment moves from diagnosis to an out-of-pocket commitment.
What the pattern means: Meibography is valued primarily as confirmation, not as the sole reason to treat. The 81.8% majority still anchors acceptance in symptoms, staining, tear-film findings, and clinical judgment.
Practice insight: Imaging is most useful when it makes an established clinical story visible. It should strengthen shared understanding rather than become a sales substitute for a complete ocular surface assessment.
What the pattern means: Financial shock is more than twice as common as value skepticism. Patients are not only asking whether treatment works; they are confronting an unfamiliar payment model inside a healthcare setting.
Practice insight: Transparent fees, expected session counts, staged options, and a clear explanation of what home care has not achieved may be more effective than simply adding more technical persuasion.
IPL leads the technology preference, but clinic design determines whether it can scale
Technology preference and practice scalability are linked, because procedure success depends on patient selection, repeat visits, staffing, and protected time.
What the pattern means: IPL leads, with thermal expression as the main alternative. The preference suggests that many optometrists are looking beyond temporary lubrication toward interventions aimed at inflammatory and gland-related drivers.
Practice insight: Device choice should follow the mechanism being treated and the practice’s capacity to deliver a complete treatment course. A popular platform cannot compensate for weak selection or inconsistent follow-up.
What the pattern means: No single operational barrier dominates, but chair time leads capital, retail-model resistance, and staffing. The first constraint is therefore often the calendar around the technology, not the technology itself.
Practice insight: Dedicated ocular surface blocks, technician-led diagnostics, and separate counseling time may unlock more capacity than placing advanced testing inside a standard refractive lane.
Reimbursement may determine whether advanced care stays specialized or becomes mainstream
The preferred future changes point to economics at both ends of the pathway: affordability for patients and viable investment for practices.
What the pattern means: Reimbursement and lower-cost portable devices together account for 77.3% of responses, while certification is selected by only 4.5%. Optometrists are signalling that knowledge is not the main barrier to broader adoption.
Practice insight: Mechanism-driven dry eye care will remain concentrated in specialized settings until payment models and equipment economics allow smaller practices to deliver it sustainably.
What this means for optometry practices
Move from escalation by habit to escalation by mechanism
The data supports a staged approach in which home care, prescription therapy, diagnostics, and procedures are connected to the underlying mechanism rather than added as isolated steps. Clear transition criteria can make advanced treatment feel clinically necessary instead of commercially optional.
Protect time for ocular surface care
Dry eye work cannot be compressed into a routine refraction lane. Practices that want to build credible medical dry eye services need dedicated diagnostic time, trained support staff, and a clear follow-up pathway.
Make value visible without letting imaging replace judgment
Objective images can strengthen patient understanding, but the peer pattern suggests that symptoms, staining, tear-film findings, and clinician interpretation remain central. Imaging should support the conversation, not become the conversation.
Endocrinology, Diabetes & Metabolism
7Oncology & Hematology
7Hospital Administration
6Dermatology
6Ophthalmology
6Gastroenterology & Hepatology
6Pharmacy
6Primary Care & Family Medicine
6Surgery & Procedural Care
5Diabetes, Weight & Metabolic Health
5Neurology
5Dentistry & Oral Health
5Nurses, NPs & Physician Assistants
5Pediatrics
5
Cardiology
4Laboratory & Diagnostics
4Radiology & Imaging
3Optometry & Optical Care
3Skin & Aesthetic Care
2Cancer Care
1Social Work & Patient Support
1Brain, Nerves & Mental Health
1
You have read the summary
The findings go deeper.
So can your participation.
Common questions readers ask about this topic
When should chronic dry eye treatment move beyond artificial tears?
Treatment may need to move beyond lubricants when symptoms persist, when meibomian gland dysfunction or inflammation is identified, or when the ocular surface shows ongoing damage. TFOS DEWS II recommends a staged, mechanism-based approach rather than relying on one therapy for every patient.
What is meibomian gland dysfunction and why does it matter?
Meibomian gland dysfunction affects the oil layer of the tear film and can increase evaporation, instability, irritation, and inflammation. Management may combine lid care, prescription therapy, thermal treatment, gland expression, or other procedures according to the clinical mechanism.
Can IPL help patients with evaporative dry eye?
Intense pulsed light is used in selected patients with evaporative dry eye and meibomian gland dysfunction. Suitability depends on diagnosis, skin type, ocular findings, contraindications, and the treatment protocol used by the eye care professional.
How is Demodex blepharitis identified?
Collarettes at the base of the eyelashes are a key clinical sign. The FDA-approved label for lotilaner ophthalmic solution describes its use for Demodex blepharitis, while slit-lamp examination remains important for identifying the lid-margin findings that prompt treatment.
Why is meibography used in dry eye care?
Are advanced dry eye procedures covered by insurance?
Coverage varies by country, payer, procedure, and indication. Patients may face out-of-pocket costs, so practices should explain the clinical rationale, expected treatment course, alternatives, and likely fees before care begins.
Related Reports
Direct answers to the questions healthcare professionals are most likely to ask about these findings.
